Patents by Inventor Kerstin Paulus

Kerstin Paulus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10603384
    Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: March 31, 2020
    Assignee: AICURIS GMBH & CO. KG
    Inventors: Kerstin Paulus, Wilfried Schwab, Dominique Grunder, Peter Van Hoogevest
  • Patent number: 10137117
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: November 27, 2018
    Assignee: AiCuris Anti-Infective Cures GmbH
    Inventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
  • Patent number: 9889124
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5 -(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2 -pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: February 13, 2018
    Assignee: AICURIS ANTI-INFECTIVE CURES GMBH
    Inventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
  • Publication number: 20170348297
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Application
    Filed: August 22, 2017
    Publication date: December 7, 2017
    Applicant: AiCuris Anti-Infective Cures GmbH
    Inventors: Wilfried SCHWAB, Alexander BIRKMANN, Kerstin PAULUS, Kurt VÖGTLI, Dieter HAAG, Stephan MAAS, Kristian RUEPP
  • Patent number: 9637459
    Abstract: The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use thereof as antiviral agents, more particularly against cytomegaloviruses.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: May 2, 2017
    Assignee: AICURIS GMBH & CO KG.
    Inventors: Alfons Grunenberg, Mathias Berwe, Birgit Keil, Edwin Aret, Kerstin Paulus, Wilfried Schwab
  • Patent number: 9592225
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 14, 2017
    Assignee: AICURIS ANTI-INFECTIVE CURES GMBH
    Inventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
  • Publication number: 20160008341
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Application
    Filed: August 31, 2015
    Publication date: January 14, 2016
    Applicant: AICURIS GMBH & CO. KG
    Inventors: Wilfried SCHWAB, Alexander BIRKMANN, Kerstin PAULUS, Kurt VOGTLI, Dieter HAAG, Stephan MAAS, Kristian RUEPP
  • Publication number: 20150366849
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 24, 2015
    Applicant: AICURIS GMBH & CO. KG
    Inventors: Wilfried SCHWAB, Alexander BIRKMANN, Kerstin PAULUS, Kurt VOGTLI, Dieter HAAG, Stephan MAAS, Kristian RUEPP
  • Patent number: 9119786
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 1, 2015
    Assignee: AICURIS GMBH & CO KG
    Inventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
  • Publication number: 20150133461
    Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
    Type: Application
    Filed: February 28, 2013
    Publication date: May 14, 2015
    Applicant: AICURIS GMBH & CO. KG
    Inventors: Kerstin Paulus, Wilfried Schwab, Dominique Grunder, Peter Van Hoogevest
  • Publication number: 20150038514
    Abstract: The invention relates to sodium and calcium salts of {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid and solvates thereof, to the use thereof in a method of treatment and/or prophylaxis of virus infections and to the use thereof for producing drugs for use in methods of treatment and/or prophylaxis of diseases, more particularly the use thereof as antiviral agents, more particularly against cytomegaloviruses.
    Type: Application
    Filed: February 28, 2013
    Publication date: February 5, 2015
    Inventors: Alfons Grunenberg, Mathias Berwe, Birgit Keil, Edwin Aret, Kerstin Paulus, Wilfried Schwab
  • Publication number: 20140065224
    Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
    Type: Application
    Filed: November 1, 2013
    Publication date: March 6, 2014
    Applicant: AICURIS GMBH & CO. KG
    Inventors: Wilfried SCHWAB, Alexander BIRKMANN, Kerstin PAULUS, Kurt VOGTLI, Dieter HAAG, Stephan MASS, Kristian RUEPP
  • Publication number: 20130296423
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Patent number: 8501723
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 6, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
  • Publication number: 20100130606
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 27, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20090117159
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: December 23, 2008
    Publication date: May 7, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventors: Hans-Jurgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20080138421
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: June 7, 2007
    Publication date: June 12, 2008
    Inventors: Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner